A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)Todd M. Cooper, Patrick A. Brown, Sharyn D. Baker et al.|Pediatric Blood & Cancer|2017Cited by 73
Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD–Positive AMLMegan E. Zavorka Thomas, Sharyn D. Baker|Molecular Cancer Therapeutics|2021Cited by 45
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AMLChristina D. Drenberg, Sharyn D. Baker|Nature Communications|2019Cited by 41
Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemiaJolieke G. van Oosterwijk, Sharyn D. Baker|Journal of Clinical Investigation|2017Cited by 39